Annals of Oncology

Edit Your Profile

Annals of Oncology Journal

publication venue for

Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer5. 36. 2025
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. 32:787-800. 2021
Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. 30:115-123. 2019
419P Double blind concordance study of colo-rectal cancer treatment recommendations between artificial intelligence advisory programme watson for oncology (WFO) & multidisciplinary tumor board (MDT). 29:viii137. 2018
Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. 29:418-423. 2018
159TiP TTFields and radiosurgery for 1-10 brain metastases from NSCLC: The Phase 3 METIS study. 28:ii55. 2017
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). 28:505-511. 2017
428P Phase 1 Study of Veliparib With Concurrent Whole Brain Radiation Therapy (WBRT) in Patients (PTS) With Brain Metastases (METS). 23:ix148-ix149. 2012
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: Survival, surgery, and organ preservation. 20:921-927. 2009
Double blind concordance study of colo- rectal cancer treatment recommendations between artificial intelligence advisory programme watson for oncology (WFO) & multidisciplinary tumor board (MDT) 2018
TTFields and radiosurgery for 1-10 brain metastases from NSCLC: The Phase 3 METIS study 2017
METIS: A phase III study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC 2016
PHASE 1 STUDY OF VELIPARIB WITH CONCURRENT WHOLE BRAIN RADIATION THERAPY (WBRT) IN PATIENTS (PTS) WITH BRAIN METASTASES (METS) 2012
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. 2020
Radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial 2019
Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra-and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC) 2019

International Standard Serial Number (ISSN)

0923-7534

Electronic International Standard Serial Number (EISSN)

1569-8041